Two drug manufacturers asked the U.S. Supreme Court on Saturday to temporarily restore mail-order access to the abortion pill mifepristone [1].
The request seeks to overturn a restriction that would require patients to pick up the medication in person. This change threatens to limit telehealth access to abortion care even in states where the procedure remains legal.
Danco Laboratories and GenBioPro filed the emergency petitions on May 2, 2026 [2]. The companies are challenging a ruling issued by the 5th U.S. Circuit Court of Appeals, which limited the distribution of the drug. The drugmakers argue that the current restrictions create an undue burden on patients who rely on mail-order services for reproductive healthcare.
By requiring in-person pickup, the 5th Circuit ruling effectively blocks the use of telehealth for prescribing mifepristone. The two companies [1] contend that this mandate ignores the safety and efficacy of the drug when administered via remote consultation and postal delivery.
The petition asks the high court to intervene and restore the previous status quo while the legal challenge proceeds. If the court denies the request, the requirement for in-person pickup could remain a nationwide limitation on how the medication is accessed.
The legal battle centers on whether the government can restrict the delivery method of a drug that has been widely used in telehealth settings. The drugmakers said the restriction is an unnecessary barrier to healthcare access.
“Two drug manufacturers asked the U.S. Supreme Court on Saturday to temporarily restore mail-order access to the abortion pill mifepristone.”
This legal action highlights a growing conflict between judicial rulings and the expansion of telehealth. If the Supreme Court refuses to intervene, the ruling by the 5th Circuit could establish a precedent that prioritizes physical pharmacy pickup over digital health services, potentially reducing the availability of reproductive care regardless of state-level legality.
